Apokyn (Apomorphine HCl) Patent Expiration, LOE Window & CMS Spending

Apokyn (Apomorphine HCl) by Mdd Us Operations: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $72.5M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMdd Us Operations
FDA Application & PathwayN021264 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$72.5M
2024 Medicare Part D Spend$70.4M
2024 Medicaid Spend$2.1M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 28.1% 2-yr change)